Eyenovia Inc (EYEN)
$0.48
+0.01
(+2.48%)▲
Performance
- $0.46$0.49$0.48
4.15%
Downside
Day's Volatility :6.06%
Upside
2.0%
- $0.37$2.57$0.48
22.92%
Downside
52 Weeks Volatility :85.6%
Upside
81.32%
Returns
| Period | Eyenovia Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -46.36% | 0.0% |
6 Months | -35.47% | 0.0% |
1 Year | -69.81% | 0.0% |
3 Years | -92.03% | -20.1% |
Highlights
Market Capitalization | 37.7M |
Book Value | - $0.04 |
Earnings Per Share (EPS) | -0.78 |
Wall Street Target Price | 10.83 |
Profit Margin | 0.0% |
Operating Margin TTM | -51661.19% |
Return On Assets TTM | -92.94% |
Return On Equity TTM | -914.66% |
Revenue TTM | 31.4K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 400.0% |
Gross Profit TTM | 12.4M |
EBITDA | -34.8M |
Diluted Eps TTM | -0.78 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.66 |
EPS Estimate Next Year | -0.54 |
EPS Estimate Current Quarter | -0.15 |
EPS Estimate Next Quarter | -0.15 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 2156.25%
Technicals Summary
Sell
Neutral
Buy
Eyenovia Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Eyenovia Inc | -4.66% | -35.47% | -69.81% | -92.03% | -87.1% |
 Regeneron Pharmaceuticals, Inc. | -10.33% | 8.11% | 21.28% | 85.63% | 257.49% |
 Novo Nordisk A/s | -12.25% | -9.71% | 24.92% | 138.38% | 343.21% |
 Alnylam Pharmaceuticals, Inc. | 9.22% | 72.73% | 52.35% | 34.04% | 250.13% |
 Vertex Pharmaceuticals Incorporated | -3.09% | 12.2% | 25.77% | 150.7% | 163.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Eyenovia Inc | NA | NA | NA | -0.66 | -9.15 | -0.93 | NA | -0.04 |
Regeneron Pharmaceuticals, Inc. | 27.55 | 27.55 | 1.42 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.7 | 38.7 | 1.75 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Eyenovia Inc | Buy | $37.7M | -87.1% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $114.7B | 257.49% | 27.55 | 32.04% |
Novo Nordisk A/s | Buy | $518.0B | 343.21% | 38.7 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.9B | 250.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $119.3B | 163.62% | 32.84 | -4.74% |
Insights on Eyenovia Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 52.3% return, outperforming this stock by 122.1%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 34.0% return, outperforming this stock by 126.0%
Institutional Holdings
Armistice Capital, LLC
7.88%Vanguard Group Inc
2.45%Lasry Marc
0.71%Geode Capital Management, LLC
0.53%Millennium Management LLC
0.51%Goldman Sachs Group Inc
0.47%
Company Information
eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.
Organization | Eyenovia Inc |
Employees | 57 |
CEO | Dr. Tsontcho Ianchulev M.D., M.P.H., MPH |
Industry | Health Technology |
Discover More
Eagle Pharmaceuticals Inc.
$0.48
+2.48%
Graniteshares 2x Long Baba Daily Etf
$0.48
+2.48%
Mingteng International Corp Inc
$0.48
+2.48%
Direct Digital Holdings Inc
$0.48
+2.48%
Dt Cloud Star Acquisition Corporation Right
$0.48
+2.48%
Precipio Inc
$0.48
+2.48%
Venus Concept Inc
$0.48
+2.48%
Fidelity Msci Materials Etf
$0.48
+2.48%
Inspire International Etf
$0.48
+2.48%